Physician profile
Jennifer A Drake
NPI 1437367570
$17,287.91
in general payments reported to CMS, 2019-2025
74 companies · $4,243 in 2025
The $4,243 reported for 2025 was more than what 83% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,349 · 2020: $1,970 · 2021: $1,947 · 2022: $2,520 · 2023: $2,914 · 2024: $2,344 · 2025: $4,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,129 · Education: $223 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,128.77 |
| Education | $222.81 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,699.19 | 2020-2025 | Ubrelvy, Botox, Qulipta |
| Ucb, INC. | $1,210.92 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Sk Life Science, INC. | $866.48 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $811.23 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $674.42 | 2019-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $636.62 | 2020-2025 | Mavenclad |
| Amgen INC. | $556.60 | 2019-2025 | Aimovig, Uplizna |
| Jazz Pharmaceuticals INC. | $525.14 | 2019-2025 | |
| Pfizer INC. | $517.64 | 2019-2025 | |
| Genzyme Corporation | $512.92 | 2019-2025 | |
| Harmony Biosciences LLC | $483.20 | 2020-2025 | Wakix |
| Neurocrine Biosciences, INC. | $446.54 | 2019-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $426.21 | 2019-2025 | Kisunla, Reyvow, Emgality |
| Genentech USA, INC. | $398.53 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Allergan, INC. | $398.13 | 2020-2022 |
Show all 73 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Drake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.